Pulse Biosciences
Medical device company developing and commercializing nanosecond pulsed field ablation (nsPFA) technology for nonthermal, cell-targeting tissue ablation. The company designs generator consoles and multiple applicators (percutaneous electrodes, catheter systems, surgical clamps), conducts preclinical and first-in-human clinical studies (cardiac and soft-tissue indications), and has an IP portfolio supporting platform expansion into multiple therapy areas.
Industries
Nr. of Employees
medium (51-250)
Pulse Biosciences
Patents
Electrical applicators for applying energy to tissue surfaces or regions superficial to the surface
US-12667717-B2
View DetailsApparatuses and methods for limiting load current in nanosecond pulsed power sources
US-12465775-B2
View Details
Electrical applicators for applying energy to tissue surfaces or regions superficial to the surface
US-12667717-B2
View DetailsApparatuses and methods for limiting load current in nanosecond pulsed power sources
US-12465775-B2
View DetailsProducts
Percutaneous electrode soft-tissue ablation system (nsPFA-based)
Percutaneous electrode system delivering nanosecond pulsed field energy for nonthermal ablation of soft tissue nodules (indicated for soft tissue; FDA cleared for percutaneous use in the U.S.).
Endocardial 360-degree nsPFA catheter system (investigational)
A multi-electrode endocardial catheter system designed to deliver nsPFA energy circumferentially for pulmonary vein isolation with integrated sensing electrodes and console integration; investigational device.
Surgical cardiac clamp nsPFA system (investigational)
Parallel-jaw cardiac clamp devices in multiple jaw lengths and an nsPFA console designed for open surgical ablation during concomitant cardiac procedures; investigational device.
nsPFA generator console
Control console that generates nanosecond pulsed field energy with touchscreen interface and foot pedal, intended to interface with multiple applicators and provide controlled therapy delivery.
Percutaneous electrode soft-tissue ablation system (nsPFA-based)
Percutaneous electrode system delivering nanosecond pulsed field energy for nonthermal ablation of soft tissue nodules (indicated for soft tissue; FDA cleared for percutaneous use in the U.S.).
Endocardial 360-degree nsPFA catheter system (investigational)
A multi-electrode endocardial catheter system designed to deliver nsPFA energy circumferentially for pulmonary vein isolation with integrated sensing electrodes and console integration; investigational device.
Surgical cardiac clamp nsPFA system (investigational)
Parallel-jaw cardiac clamp devices in multiple jaw lengths and an nsPFA console designed for open surgical ablation during concomitant cardiac procedures; investigational device.
nsPFA generator console
Control console that generates nanosecond pulsed field energy with touchscreen interface and foot pedal, intended to interface with multiple applicators and provide controlled therapy delivery.
Expertise Areas
- Nonthermal pulsed field ablation
- Cardiac electrophysiology ablation
- Percutaneous soft-tissue ablation
- Medical device design and engineering
Key Technologies
- Nanosecond pulsed field ablation (nsPFA)
- Nonthermal cell-targeting electrical ablation
- Catheter-based multi-electrode ablation
- Percutaneous electrode ablation systems
News & Updates
Preclinical study comparing nanosecond pulses to microsecond pulses at matched energy showed deeper cardiac lesions with nanosecond PFA.
Presentation of clinical data reporting successful treatment of atrial fibrillation in 150 patients with rapid procedure times and minimal adverse effects from an nsPFA cardiac catheter system.
Reporting favorable durability of pulmonary vein isolation in initial patients treated in a first-in-human feasibility study.
Company submitted two 510(k) applications for a surgical cardiac clamp and a percutaneous electrode leveraging nsPFA energy; devices were described as investigational and not yet cleared at the time of announcement.
Reported use of the nsPFA system to treat over 6,000 patients outside of cardiology.
Reported ownership and licensing of over 130 issued patents globally.
Preclinical study comparing nanosecond pulses to microsecond pulses at matched energy showed deeper cardiac lesions with nanosecond PFA.
Presentation of clinical data reporting successful treatment of atrial fibrillation in 150 patients with rapid procedure times and minimal adverse effects from an nsPFA cardiac catheter system.
Reporting favorable durability of pulmonary vein isolation in initial patients treated in a first-in-human feasibility study.
Company submitted two 510(k) applications for a surgical cardiac clamp and a percutaneous electrode leveraging nsPFA energy; devices were described as investigational and not yet cleared at the time of announcement.
Reported use of the nsPFA system to treat over 6,000 patients outside of cardiology.
Reported ownership and licensing of over 130 issued patents globally.